A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity by Sylvana Hidalgo, Carol A. Albright, Gretchen L. Wells

“…Trastuzumab is a monoclonal antibody highly effective in the treatment of several cancers, but its use is associated with cardiac toxicity which usually responds to cessation of the drug and/or medical therapy. …”
Get full text

Trastuzumab Resistance: Role for Notch Signaling by Kinnari Mehta, Clodia Osipo

“…However, resistance to trastuzumab remains a major concern, most notably in women with metastatic breast cancer. …”
Get full text

Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab by Lauren Klute, Matthew Solverson, Christopher M. Bingcang, Jayme R. Dowdall

“…We present a case of hemoptysis in a young female patient undergoing treatment for metastatic breast cancer with trastuzumab emtansine. Though previously associated with diffuse spontaneous hemorrhage of the gingiva, there have not been reports of laryngeal hemorrhage with trastuzumab emtansine treatment. …”
Get full text

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer by Abul Azad, Maryam Arshad, Daniele Generali, Katharina Feldinger, Merel Gijsen, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Russell Leek, Syed Haider, Pirkko‐Liisa Kellokumpu‐Lehtinen, Ioannis Roxanis, Adrian Llewellyn Harris, Abeer Mahmoud Shaaban, Heikki Joensuu, Anthony Kong

Get full text

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer by Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho

Subjects: “…Trastuzumab-Deruxtecan…”
Get full text

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens by Özlem Yersal, Ufuk Eryilmaz, Hakan Akdam, Nezih Meydan, Sabri Barutca

“…The aim of this study is to analyze the arterial stiffness in breast cancer patients who are in the follow-up period after receiving anthracycline-based chemotherapy regimens with trastuzumab. Methods and Material. We enrolled 45 HER2-positive breast cancer patients who are on follow-up at least for six months after completion of adjuvant chemotherapy with trastuzumab, and cardiovascular risk matched 30 control volunteers. …”
Get full text

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma by Muhammad Shahid Iqbal, Ghazia Shaikh, Sanjoy Chatterjee, Helen Cocks, Josef Kovarik

“…A significant percentage of SDCs overexpress Her2 and the use of targeted therapy with trastuzumab can be considered in these patients. We report a rare case of long term disease control with trastuzumab in Her2 positive metastatic parotid ductal carcinoma. …”
Get full text

Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan by Alessandra Fabi, Alessandro Rossi, Roberta Caputo, Simona Pisegna, Simone Scagnoli, Francesco Pantano, Giuliana D’Auria, Palma Fedele, Agnese Fabbri, Claudio Vernieri, Michela Palleschi, Luisa Carbognin, Gianluigi Ferretti, Elena Di Monte, Ida Paris, Francesco Pavese, Ornella Garrone, Antonio Franco, Michelino De Laurentiis, Gianluca Franceschini, Giovanni Scambia, Diana Giannarelli, Riccardo Masetti, Andrea Botticelli

“…Recent results demonstrated high intracranial efficacy with Trastuzumab Deruxtecan (T-DXd). However, a real-world evidence is lacking in literature. …”
Get full text

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer by Andrea L. A. Wong, Soo-Chin Lee

“…While anti-HER2 agents such as trastuzumab and lapatinib are integral to the treatment of HER2-positive breast cancer, intrinsic and secondary resistance pose a significant challenge, underscoring the need to develop novel anti-HER2 therapies. …”
Get full text

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus by Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi

Subjects: Get full text

Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany by Kirsten Merx, Manuel Barreto Miranda, Lenka Kellermann, Ulrich Mahlknecht, Oliver Lange, Michael Gonnermann, Ralf-Dieter Hofheinz

“…Usage of the combination of fluoropyrimidines and cisplatin with trastuzumab declined from 67% in cohort 1 to 50% in cohort 2.…”
Get full text

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient by Nu T. Lu, Jeffrey Raizer, Erwin P. Gabor, Natalie M. Liu, James Q. Vu, Dennis J. Slamon, John L. Barstis

“…We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination therapy with intravenous (IV) trastuzumab. Due to progressive CNS disease, intrathecal (IT) trastuzumab was introduced to enhance HER-2+ therapy into the CSF space. …”
Get full text

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer by Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen

“…The safety and tolerability of trastuzumab emtansine (T-DM1) combined with pembrolizumab is unknown.Methods This was a single-arm phase Ib trial (registration date January 26, 2017) of T-DM1 plus pembrolizumab in metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. …”
Get full text

A Cost-Effective and Robust Cell-Based Bioassay Method for Evaluating the Bioactivity of Trastuzumab-like Antibodies by Pooja Bharali, Subhash Chand, Harish Chander

Subjects: “…trastuzumab…”
Get full text

Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature by Cristina Dumitrescu, Dominique Lossignol

“…We report the case of a 65-year-old woman, diagnosed with a breast cancer human epidermal growth factor receptor (HER2) previously negative, who developed leptomeningeal carcinomatosis and was treated with intrathecal (IT) trastuzumab (TST). After five doses of IT trastuzumab, at escalading doses, once weekly, the patient's neurological status stabilised, and that result was maintained for two months. …”
Get full text

Prognosis and cardiotoxicity associated to adjuvant trastuzumab for breast cancer: real world study in a public health system by Ana Elisa Ribeiro da Silva Cabello, César Cabello, Susana Oliveira Botelho Ramalho, Otávio Rizzi Coelho, Otávio Rizzi Coelho-Filho, Helymar da Costa Machado, Délio Marques Conde, Luiz Carlos Zeferino

Subjects: Get full text

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer by Asiye Busra Boz Er

Subjects: Get full text

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer by Satomi Watanabe, Kimio Yonesaka, Junko Tanizaki, Yoshikane Nonagase, Naoki Takegawa, Koji Haratani, Hisato Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Junji Tsurutani, Kazuhiko Nakagawa

“…Abstract HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. …”
Get full text

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre by Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah

Subjects: “…trastuzumab…”
Get full text

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan by Ünal Metin Tokat, Ashkan Adibi, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Subjects: Get full text